Project Grant R01CA314300
- Federal Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded Cedars-Sinai Medical Center a $708,990 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This award supports fundamental research investigating the microenvironmental and hepatocyte cell-type specific regulation of colorectal cancer (CRC) metastasis by the IL-17 cytokine. Research Scope and Deliverables: The project aims to elucidate...
- Federal Grant Award Summary Cedars-Sinai Medical Center received an $858,798 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on August 18, 2025, with completion targeted for July 31, 2027. This R21 grant, led by two principal investigators with complementary expertise in extracellular vesicles (EVs) and circular RNA (circRNA), investigates novel immunosuppressive mechanisms in prostate cancer—a leading cause of cancer-related...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $695,634 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) to investigate cytokine and B cell regulation of the immune tumor microenvironment in hepatocellular carcinoma (HCC). Awarded on May 7, 2026, with completion targeted for April 30, 2031, this research project focuses on elucidating the role of Interleukin-27 (IL-27) receptor signaling in controlling B cell...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $679,353 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. The award funds research investigating the protective role of PYDC5 (Pyrin and DM1 domains containing 5) in colorectal cancer development and progression. The research will elucidate how PYDC5 expression in intestinal macrophages influences the tumor immune...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $743,264 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded June 23, 2026, with completion targeted for May 31, 2031. The grant funds research integrating high-resolution elemental mapping with spatial transcriptomics to analyze metal-based pathways in tumor growth and metastasis. The project addresses a critical gap in understanding...
- Federal Project Grant Award Summary Award Details: Cedars-Sinai Medical Center received a $662,610 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective April 1, 2026, through March 31, 2031. The award supports research on universal methylated circulating tumor DNA (ctDNA) markers for minimal residual disease (MRD) detection and therapy response prediction in colorectal cancer. Products and Services: The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $648,626 to the University of California Irvine on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support a five-year project extending through March 31, 2031. This Project Grant funds fundamental research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically examining how PD-1 (Programmed Death-1) inhibition affects tumor...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $653,568 Project Grant to the University of California, Los Angeles, effective July 1, 2026, through June 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). The award supports research to enhance antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The project develops and evaluates drug candidates designed to improve the efficacy of existing cancer immunotherapies,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $574,557 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective June 15, 2026, through May 31, 2031. The grant funds research to integrate life expectancy (LE) estimates into electronic health record (EHR) decision support systems for men with prostate cancer (PC). The project addresses a critical clinical need, as life expectancy is the primary...
Award Details:
The National Cancer Institute (NCI) awarded Cedars-Sinai Medical Center a $627,733 Project Grant under the Cancer Biology Research program (CFDA 93.396) on July 3, 2026, with a project completion date of June 30, 2031. The research will be conducted in West Hollywood, California. Research Products and Services:
This grant funds a five-year investigation into the immunosuppressive mechanisms of itaconate, a metabolite produced by immune-responsive gene 1 (IRG1), and its role in suppressing CD8+ T cell-mediated anti-tumor immunity within the tumor microenvironment. The research will characterize how CD8+ T cells uptake itaconate secreted from immune-suppressive myeloid cells and investigate the molecular mechanisms underlying this immunosuppression. The project leverages preliminary findings demonstrating that IRG1 knockout reduces tumor growth in melanoma and colorectal cancer models while enhancing anti-PD-1 antibody efficacy. Deliverables include identification of candidate transporters mediating itaconate uptake, mechanistic characterization of metabolite biosynthesis perturbations, and development of therapeutic strategies targeting the itaconate pathway to restore anti-tumor CD8+ T cell function. This fundamental research aligns with the NCI's Cancer Biology Research program objective to provide mechanistic insights into cancer immunology that inform improved cancer prevention, detection, and treatment approaches.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $627.7k | 7/7/26 |